Vancomycin

Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update

Retrieved on: 
Jeudi, mars 30, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, APAP, Inc., Research, Vancomycin, Investment, COVID, Safety, Chair, Pharmaceutical industry, Video game, Cryptocurrency, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update.
  • Research and development expenses were $7.6 million for the fourth quarter of 2022, which were equivalent to the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 and 2021 were $3.2 million and $3.0 million, respectively.
  • As of December 31, 2022, the Company had cash, cash equivalents and short-term investments of $125.9 million.

PrecisePK Expands Its Global Standing as The Most Trusted Bayesian Dosing Software for South Korea's Health Systems

Retrieved on: 
Lundi, mars 27, 2023
Tacrolimus, Kyung Hee University, Pharmacy, Therapeutic drug monitoring, Health, Bed, Infection, Pharmacokinetics, Research, Asan Medical Center, Acute kidney injury, Hospital, Vancomycin, Guideline, SAN, AUC, Busulfan, Medicine, Cardiology, Neurology, Health care, Pharmaceutical industry

SAN DIEGO, March 27, 2023 /PRNewswire/ -- Today, PrecisePK, an industry-trusted Bayesian Model-Informed Precision Dosing (MIPD) software, reports its technology is being implemented in many of South Korea's largest health systems.

Key Points: 
  • SAN DIEGO, March 27, 2023 /PRNewswire/ -- Today, PrecisePK, an industry-trusted Bayesian Model-Informed Precision Dosing (MIPD) software, reports its technology is being implemented in many of South Korea's largest health systems.
  • PrecisePK proudly offers drug models for more than 20 medications, including vancomycin, busulfan, tacrolimus, and many others, effectively delivering precision dosing to around 6,000 beds across these hospitals.
  • PrecisePK spearheads the worldwide application of Bayesian MIPD, trusted by additional major South Korean hospitals.
  • PrecisePK aims to enhance patient care by providing cutting-edge technology and empowering global healthcare professionals to ensure medication safety at international standards.

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Retrieved on: 
Mardi, mars 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Methicillin-resistant Staphylococcus aureus, NYSE, Infection, VRE, Daptomycin, Phenotype, Enterococcus-1 RNA motif, Methicillin, MRSA, Vancomycin, Oxacillin, Vaccine, Antibiotics, Oragene

Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Key Points: 
  • Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.
  • Oragenics’ lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
  • Oragenics is focused on addressing this unmet medical need through its novel lantibiotics platform, and the results of its work with Linnaeus Bioscience advance Oragenics’ long-term mission to become a provider of effective treatments for infectious diseases.
  • Oragenics remains committed to fighting infectious diseases through the development of its lantibiotics pipeline against MRSA and VRE pathogens.

InsightRX Continues Accelerated Growth with Life Sciences Organizations and Health Systems

Retrieved on: 
Mardi, mars 14, 2023
Machine learning, Research, Tacrolimus, Software, AI, Data, Medicine, BCPS, Pharming, Optimus, Food and Drug Administration Amendments Act of 2007, Hospital, Rare, Patient, Pharmacology, Food, Continuity, Growth, Apollo, FDA, SAN, Vancomycin, Medical device, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, March 14, 2023 /PRNewswire/ -- InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – capped off another successful year in 2022. The company made remarkable progress in the development of its two core platforms, InsightRX Nova, an application designed to individualize drug dosing, and InsightRX Apollo, a real-time analytics application that aims to understand and improve drug performance across different patient populations. InsightRX's ongoing innovation is evidence of its commitment to advancing precision medicine and improving patient outcomes.

Key Points: 
  • In 2022, the company not only retained all its health system and life sciences customers but also expanded its customer base to include nearly 700 inpatient hospitals.
  • "We're immensely proud that within U.S. health systems, at peak, a patient is dosed using InsightRX Nova nearly every second," said Sirj Goswami, Ph.D., chief executive officer and co-founder of InsightRX.
  • InsightRX also experienced continued growth in the biopharmaceutical industry in 2022, as companies sought more comprehensive dose finding strategies bolstered by integrated cloud software.
  • InsightRX continues to support agency initiatives regarding precision dosing and individualized medicine, highlighted by Project Optimus .

Large-scale, peer-reviewed study quantifies multiple devastating patient harms associated with blood culture contamination and most significantly, a 74% increase in risk of in-hospital patient mortality

Retrieved on: 
Mardi, janvier 24, 2023
BMI, Safety, Vancomycin, University, Blood culture, University of Arkansas, Medical Center, Invention, Emergency department, Medical director, Culture, Entrepreneurship, Associate, Infection, Fungal infection, Infection Control & Hospital Epidemiology, Hospital, Acute kidney injury, Risk factor, Patient safety, FDA, Growth, UAMS, Antimicrobial stewardship, Length of stay, Patient, Sepsis, Risk, Body mass index, Mortality, HAI, Magnolia, Clostridioides difficile infection, CDI, Medicine, Pharmaceutical industry, Nursing

SEATTLE, Jan. 24, 2023 /PRNewswire/ -- Magnolia Medical Technologies, Inc. ("Magnolia Medical"), inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®), the only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination for sepsis testing accuracy1, today shared the publication of recent clinical results from the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas. This four-year retrospective analysis examined the clinical and financial impacts of blood culture contamination on patient safety, outcomes, and in-hospital patient mortality.

Key Points: 
  • This four-year retrospective analysis examined the clinical and financial impacts of blood culture contamination on patient safety, outcomes, and in-hospital patient mortality.
  • Blood culture is one of the most frequently performed diagnostic tests in U.S. hospitals with an estimated 58 million tests each year.
  • However, positive blood culture results are frequently wrong, with approximately 40% of positive results returning a false-positive result due to contamination.
  • "It is imperative for hospital systems to make decreasing blood culture contamination a priority to improve safety for patients under our care.

Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection

Retrieved on: 
Mardi, février 7, 2023
Principal, Cleveland Clinic, Vancomycin, APEX, Tobramycin, Patient, Hip, Knee, Cleveland, Therapy, Pharmaceutical industry, MD

APEX-2 is a multicenter, randomized controlled clinical trial of VT-X7 (vancomycin hydrochloride and tobramycin sulfate for irrigation in adults with periprosthetic joint infections (PJI) of the hip or knee).

Key Points: 
  • APEX-2 is a multicenter, randomized controlled clinical trial of VT-X7 (vancomycin hydrochloride and tobramycin sulfate for irrigation in adults with periprosthetic joint infections (PJI) of the hip or knee).
  • APEX-2 has a planned enrollment of 76 patients with a design similar to the previous Phase 2 study, APEX, which completed subject enrollment in November.
  • Dr. Nicolas Piuzzi, MD, Cleveland Clinic Adult Reconstruction & Research (CCARR) Director and Principal Investigator for APEX-2, administered the treatment.
  • “We’re confident that VT-X7 has the potential to be a highly effective tool for treatment of orthopedic infections.

Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

Retrieved on: 
Jeudi, janvier 5, 2023
Other Health, Health, Pharmaceutical, Optical, Clinical Trials, Tobramycin, Patient, Standard of care, Optometry, Vancomycin, Ophthalmology, Multimedia, FDA, Pharmaceutical industry

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility.

Key Points: 
  • Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility.
  • Fortisite formulations are patent-pending high-concentration, refrigeration-stable, fortified antibiotic formulations, in solution.
  • The availability of Fortisite for in-office use represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients in need.
  • In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “The availability of Fortisite formulations will provide eyecare professionals with new and important tools in their pharmaceutical armamentarium as they consider how to treat potentially sight-threatening infections.

PrecisePK Collaborates with Wolters Kluwer to Enhance Dose Optimization

Retrieved on: 
Mercredi, janvier 4, 2023
Wolters Kluwer, AKI, Patient safety, Patient, Infectious Diseases Society of America, SAN, Drug development, Pharmacy management system, Vancomycin, Pharmacy, Hospital, AUC, Society, Cardiology, Big data, Neurology, Pharmaceutical industry, Health, List of things named after Thomas Bayes

PrecisePK and Wolters Kluwer join forces to advance precision dosing.

Key Points: 
  • PrecisePK and Wolters Kluwer join forces to advance precision dosing.
  • "Our PrecisePK relationship will enable our users to leverage data and information to make better medication dosing decisions, improve patient safety, and drive better clinical outcomes," said Karen Kobelski, Vice President & General Manager, Clinical Surveillance Compliance & Data Solutions, Wolters Kluwer, Health.
  • "The added capabilities of PrecisePK are synergistic with Wolters Kluwer's Sentri7 Pharmacy to add value for healthcare practitioners," says Anjum Gupta, CEO of PrecisePK.
  • We are certainly excited to collaborate with Wolters Kluwer in advancing the use and role of big data and machine learning-driven analytics for bedside clinical patient care."

InsightRX Provides Máxima Medical Center with Precision Dosing Guidance

Retrieved on: 
Mardi, décembre 13, 2022
Doctor of Pharmacy, Physician, Azole, Algorithm, Software, Acute kidney injury, Tacrolimus, Doctor of Philosophy, Piperacillin, Magnetic resonance, Partnership, IBD, Patient, Research, Hospital, Precision medicine, Therapeutic drug monitoring, Voriconazole, Sunitinib, Inflammatory bowel disease, City, Meropenem, Adalimumab, MMC, SAN, Machine learning, Vancomycin, Methotrexate, Organization, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Dec. 13, 2022 /PRNewswire/ -- Today InsightRX, a precision dosing intelligence company, announced that Máxima Medical Center (MMC), a 600-bed teaching hospital in the Netherlands, is using its cloud-based precision dosing platform to support its clinical practice and immunology research. The center relies on the InsightRX Nova platform to support accurate therapeutic drug monitoring of the antibiotic drugs vancomycin and aminoglycoside for adults, children, and neonates. Through an innovative research partnership, InsightRX Nova also provides MMC with precision dosing support and analytics for the monoclonal antibodies infliximab and adalimumab, used in the treatment of Inflammatory Bowel Disease (IBD).

Key Points: 
  • SAN FRANCISCO, Dec. 13, 2022 /PRNewswire/ -- Today InsightRX, a precision dosing intelligence company, announced that Mxima Medical Center (MMC), a 600-bed teaching hospital in the Netherlands, is using its cloud-based precision dosing platform to support its clinical practice and immunology research.
  • Through an innovative research partnership, InsightRX Nova also provides MMC with precision dosing support and analytics for the monoclonal antibodies infliximab and adalimumab, used in the treatment of Inflammatory Bowel Disease (IBD).
  • Now, the days of simply doubling the dose when patients prove nonresponsive to treatment are over," said Luc Derijks, PharmD, PhD, clinical pharmacologist at Mxima Medical Center.
  • "We look forward to a long partnership with Mxima Medical Center, which has embraced the benefits of both reactive and proactive therapeutic drug monitoring," said Sirj Goswami, CEO and co-founder of InsightRX.

InsightRX to Showcase Precision Dosing Technology at ASHP 2022 Midyear Meeting

Retrieved on: 
Jeudi, décembre 1, 2022
Antifungal, Mandalay Bay Convention Center, Doctor of Philosophy, Voriconazole, Patient, SAN, Beta-lactam, Anticoagulant, Nephrotoxicity, Literature, Pharmacokinetics, Machine learning, Risk, Patient safety, Exhibition, Health, Mortality, Magnetic resonance, Vancomycin, Toxicity, Ambiguity, BCPS, Pharmacist, Society, Senior, Tacrolimus, Nova, Doctor of Pharmacy, Precision medicine, ASHP, Infection, Pharmacy management system, Forecasting, Customer experience, AUC, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX — which provides cloud-based precision dosing support to guide treatment decisions – announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.

Key Points: 
  • SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX which provides cloud-based precision dosing support to guide treatment decisions announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.
  • At ASHP Midyear, held at the Mandalay Bay Convention Center, they will be showcasing several new therapeutic categories that are now a part of their offering.
  • 2020 brought the newest vancomycin consensus guidelines ,which firmly recommended Bayesian forecasting software as the preferred method of dosing and monitoring.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.